Back to the Top
Does anyone have experience in doing a BE/bioavailability assessment for a conversion of vials to PFS formats for monoclonals? Is it required by the regulatory agency?
What factors need to be considered when converting from vials to PFS?
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "PFS vs. Vial BE" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)